EP1819345A4 - Use of lipid conjugates in the treatment of disease - Google Patents

Use of lipid conjugates in the treatment of disease

Info

Publication number
EP1819345A4
EP1819345A4 EP05808267A EP05808267A EP1819345A4 EP 1819345 A4 EP1819345 A4 EP 1819345A4 EP 05808267 A EP05808267 A EP 05808267A EP 05808267 A EP05808267 A EP 05808267A EP 1819345 A4 EP1819345 A4 EP 1819345A4
Authority
EP
European Patent Office
Prior art keywords
disease
treatment
lipid conjugates
conjugates
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05808267A
Other languages
German (de)
French (fr)
Other versions
EP1819345A2 (en
Inventor
Saul Yedgar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/989,606 external-priority patent/US7811999B2/en
Priority claimed from US10/989,607 external-priority patent/US7772196B2/en
Priority claimed from PCT/US2005/006591 external-priority patent/WO2005084307A2/en
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of EP1819345A2 publication Critical patent/EP1819345A2/en
Publication of EP1819345A4 publication Critical patent/EP1819345A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EP05808267A 2004-11-17 2005-11-17 Use of lipid conjugates in the treatment of disease Withdrawn EP1819345A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/989,606 US7811999B2 (en) 2000-01-10 2004-11-17 Use of lipid conjugates in the treatment of diseases
US10/989,607 US7772196B2 (en) 2000-01-10 2004-11-17 Use of lipid conjugates in the treatment of diseases
PCT/US2005/006591 WO2005084307A2 (en) 2004-03-02 2005-03-02 Use of lipid conjugates in the treatment of disease
PCT/IL2005/001225 WO2006054304A2 (en) 2004-11-17 2005-11-17 Use of lipid conjugates in the treatment of disease

Publications (2)

Publication Number Publication Date
EP1819345A2 EP1819345A2 (en) 2007-08-22
EP1819345A4 true EP1819345A4 (en) 2012-04-18

Family

ID=39619055

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05808267A Withdrawn EP1819345A4 (en) 2004-11-17 2005-11-17 Use of lipid conjugates in the treatment of disease

Country Status (10)

Country Link
EP (1) EP1819345A4 (en)
JP (2) JP2008520650A (en)
CN (1) CN101175499B (en)
AU (1) AU2005305456B2 (en)
BR (1) BRPI0516810A (en)
CA (1) CA2587883A1 (en)
EA (1) EA012138B1 (en)
IL (3) IL183227A0 (en)
MX (1) MX2007005975A (en)
WO (1) WO2006054304A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
WO2008100912A1 (en) * 2007-02-12 2008-08-21 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
CN102458420A (en) * 2009-05-11 2012-05-16 以色列耶路撒冷希伯来大学伊索研究发展公司 Lipid-polymer conjugates, their preparation and uses thereof
CA2925546C (en) 2012-10-29 2022-06-14 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
WO2015005459A1 (en) * 2013-07-10 2015-01-15 生化学工業株式会社 Pharmaceutical composition for respiratory administration
JP2019518798A (en) * 2016-06-27 2019-07-04 オハイオ・ステイト・イノベーション・ファウンデーション Liponucleotide based ARDS treatment
AU2017362500B2 (en) 2016-11-17 2024-09-26 Renovion, Inc. Treatment of Respiratory Tract Diseases and Infections with Ascorbic Acid Compositions
WO2019099946A1 (en) 2017-11-17 2019-05-23 Renovion, Inc. Stable ascorbic acid compositions and methods of using the same
MX2024008001A (en) 2022-01-04 2024-07-12 Renovion Inc Aqueous solution comprising a glutathione salt.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021211A1 (en) * 1992-04-14 1993-10-28 Laboratorios Menarini S.A. Amides having inhibiting activity on phospholipase a2, a process for the preparation thereof and pharmaceutical compositions containing them
US20040087492A1 (en) * 2000-01-10 2004-05-06 Saul Yedgar Use of lipid conjugates in the treatment of diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84252A (en) * 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
JPH0232013A (en) * 1988-07-20 1990-02-01 Denki Kagaku Kogyo Kk Nasal drop
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
JP3714683B2 (en) * 1992-07-30 2005-11-09 生化学工業株式会社 Anti-rheumatic agent
DK0785773T3 (en) * 1994-10-14 2001-01-29 Liposome Co Inc Etherlipid liposomes and their therapeutic use
US6180596B1 (en) * 1995-05-18 2001-01-30 Wisconsin Alumni Research Foundation Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
JPH11147901A (en) * 1997-11-19 1999-06-02 Maruho Co Ltd Kallikrein-kinin system inhibitor
US6162787A (en) * 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
CA2397016C (en) * 2000-01-10 2011-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US7141552B2 (en) * 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021211A1 (en) * 1992-04-14 1993-10-28 Laboratorios Menarini S.A. Amides having inhibiting activity on phospholipase a2, a process for the preparation thereof and pharmaceutical compositions containing them
US20040087492A1 (en) * 2000-01-10 2004-05-06 Saul Yedgar Use of lipid conjugates in the treatment of diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHYLLIS DAN ET AL: "Inhibition of Type I and Type II Phospholipase A 2 by Phosphatidyl-Ethanolamine Linked to Polymeric Carriers +", BIOCHEMISTRY, vol. 37, no. 17, 1 April 1998 (1998-04-01), pages 6199 - 6204, XP055004270, ISSN: 0006-2960, DOI: 10.1021/bi972066l *

Also Published As

Publication number Publication date
CN101175499B (en) 2010-12-22
CN101175499A (en) 2008-05-07
EA200701077A1 (en) 2008-04-28
JP2012001559A (en) 2012-01-05
AU2005305456B2 (en) 2011-05-19
MX2007005975A (en) 2007-10-08
IL183227A0 (en) 2007-08-19
JP2008520650A (en) 2008-06-19
AU2005305456A1 (en) 2006-05-26
EP1819345A2 (en) 2007-08-22
EA012138B1 (en) 2009-08-28
WO2006054304A2 (en) 2006-05-26
IL212215A0 (en) 2011-06-30
BRPI0516810A (en) 2008-09-23
IL212214A0 (en) 2011-06-30
WO2006054304A3 (en) 2007-01-25
CA2587883A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
IL177847A0 (en) Use of lipid conjugates in the treatment of disease
IL212215A0 (en) Use of lipid conjugates in the treatment of disease
EP1781689A4 (en) Conjugates and therapeutic uses thereof
IL180078A (en) 9-cis-retinal derivative for use in the treatment of 11-cis -retinal deficiency
IL184884A0 (en) Extending time or disease progression or survival in cancer patients
GB0410725D0 (en) Pyrrolobenzodiazepine therapeutic agents
IL150628A0 (en) Use of lipid conjugates in the treatment of disease
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
PL1912650T3 (en) Use of flibanserin in the treatment of obesity
EP2094281A4 (en) Use of lipid conjugates in the treatment of diseases or disorders of the eye
EP1758605A4 (en) Prouroguanylin as therapeutic and diagnostic agents
EP1874800A4 (en) Diagnostic and therapeutic agents
HK1109736A1 (en) Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
HK1075423A1 (en) Human nosecock
EP1781685A4 (en) Therapeutic and diagnostic agents
LT1807156T (en) New pharmaceutical formulations useful in the treatment of insomnia
IL181300A0 (en) Photosensitizer formulations and uses thereof
EP1757282A4 (en) The use of kauranes compounds in the manufacture of medicament
IL185575A0 (en) Benzoxazocines and their therapeutic use
EP1951914A4 (en) Diagnostic and therapeutic methods and agents
EP1767210A4 (en) The medical use of paeoniflorin
IL229981A0 (en) Use of lipid conjugates in the treatment of disease
IL229982A0 (en) Use of lipid conjugates in the treatment of disease
IL229980A0 (en) Use of lipid conjugates in the treatment of disease
GB0402598D0 (en) Improvements in or relating to patient support

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070618

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120315

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/06 20060101ALI20120309BHEP

Ipc: A61P 11/00 20060101ALI20120309BHEP

Ipc: A61K 47/48 20060101ALI20120309BHEP

Ipc: A61K 31/728 20060101ALI20120309BHEP

Ipc: A61K 31/737 20060101ALI20120309BHEP

Ipc: A61K 31/70 20060101AFI20120309BHEP

17Q First examination report despatched

Effective date: 20130826

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160119